Martin Mattingly
Director/Board Member bei TRACON PHARMACEUTICALS, INC.
Vermögen: 341 $ am 31.03.2024
Profil
Martin A.
Mattingly is an Independent Director at TRACON Pharmaceuticals, Inc. He previously served as the Chief Executive Officer at Trimeris, Inc. and President & Chief Executive Officer at Ambrx, Inc. He was also an Independent Director at OncoGenex Pharmaceuticals, Inc. and Achieve Life Sciences, Inc. Additionally, he served as the General Manager-HIV Division at Agouron Pharmaceuticals LLC and Vice President-Global Marketing Planning at Pfizer Inc. He was the Chief Operating Officer & Executive Vice President at CancerVax Corp.
He holds a doctorate degree from the University of Kentucky.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.02.2024 | 750 ( 0,00% ) | 323 $ | 31.03.2024 | |
| 13.04.2023 | 4 ( 0,00% ) | 18 $ | 31.03.2024 |
Aktive Positionen von Martin Mattingly
| Unternehmen | Position | Beginn |
|---|---|---|
| TRACON PHARMACEUTICALS, INC. | Director/Board Member | 26.12.2014 |
Ehemalige bekannte Positionen von Martin Mattingly
| Unternehmen | Position | Ende |
|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Director/Board Member | 07.06.2023 |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Director/Board Member | 03.08.2017 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Chief Executive Officer | 01.01.2012 |
| AMBRX INC | Chief Executive Officer | 01.09.2007 |
| CancerVax Corp. | Chief Operating Officer | 01.09.2005 |
Ausbildung von Martin Mattingly
| University of Kentucky | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| TRACON PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Health Technology |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
| CancerVax Corp. | Commercial Services |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Tech Coast Angels, Inc.
 Tech Coast Angels, Inc. Investment ManagersFinance Tech Coast Angels, Inc. (Tech Coast Angels) is an angel firm founded in 1997 by Luis Villalobos. The firm is headquartered in Irvine, California. | Finance |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
| Achieve Life Sciences, Inc. |
